Anti-inflammation and anti-cancer effects of Naringenin combination with Artemisinins in human lung cancer cells

Abstract

BackgroundNaringenin is a well-known flavonoid agent with a significant anti-microbial and anti-cancer effect to induce apoptosis and suppress tumor growth in different malignancies such as lung cancer. Artemisinins, a family of sesquiterpene trioxane is known to have powerful therapeutic functions including anticancer and anti-inflammatory effects. Therefore, in the present study, we aimed to assess anti-cancer and anti-inflammation effect of Naringenin in combination with Artemisinin to develop an effective therapeutic target for lung Cancer. MethodCells were treated with Naringenin (50 μg/ml) in combination with various concentrations of Artemisinins (10–50 μg/ml). Cell viability, PKA activity, cAMP concentration and pro-inflammatory cytokines levels were determined by using MTT assay, colorimetric measurement and Enzyme-linked immunosorbent assay respectively. ResultOur results confirmed that Naringenin (50 μg/ml) combination with increasing dosage of Artemisinins could significantly inhibit cell growth, and the pro-inflammatory cytokines via increasing the PKA and cAMP levels in human A549 lung cancer cell line. ConclusionOur results indicate that Artemisinins and Naringenin combination could become an effective therapeutic agent via inhibiting the cell viability, and inflammatory cytokines in human lung cancer.